Evaxion Biotech A/S
EVAX
NASDAQ·Healthcare·Biotechnology·Mkt cap $19.7M
$3.12
▲ +1.30%
P/E
—
Mkt Cap
$19.7M
52-Wk Range
$2.71–$12.15
52-Week Range
$2.71 - $12.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 5.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI-driven immunotherapy platform enabling rapid candidate identification
- First-mover advantage in AI-powered personalized cancer vaccine development
- Multi-indication pipeline reducing development risk across oncology and infectious diseases
- Strategic focus on unmet medical needs in melanoma and immunotherapy-resistant cancers
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Advancement of EVX-01 through Phase IIb clinical trials with potential for accelerated approval pathways
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-16.4% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EVAX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 20, 2026
Reported EPS of -$0.01 vs -$0.01 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
-100%
-76%
+148%
-100%
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q1 26
Q2 26
$23.9K
$468.3K
$18.9K
$0
$5.7K
$1.2M
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Apr 24, 2026
vs Industry
How EVAX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related